💊 Medicamentos A-Z 🧬 Alvos 🛠 Ferramentas 📚 Guias
Todos os Medicamentos Classes de Medicamentos Áreas Terapêuticas Efeitos Colaterais
Guias Glossário Linha do Tempo
Comparações Percursos de Medicamentos Famílias de Medicamentos
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Afamitresgene Autoleucel

CHEMBL4802254 Phase 4 Aprovado Gene
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A personalized gene therapy that uses a patient's own T cells, which are genetically engineered to recognize and attack cancer cells expressing a specific tumor protein called MAGE-A4. The modified cells are infused back into the patient, where they seek out and destroy cancer cells while largely sparing healthy tissue.

Mecanismo de Ação

Delivers functional copies of a gene to target cells using a viral vector, restoring expression of the deficient protein and correcting the underlying genetic defect.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Delivers functional copies of a gene to target cells using a viral vector, restoring expression of the deficient protein and correcting the underlying genetic defect.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A personalized gene therapy that uses a patient's own T cells, which are genetically engineered to recognize and attack cancer cells expressing a specific tumor protein called MAGE-A4. The modified cells are infused back into the patient, where they seek out and destroy cancer cells while largely sparing healthy tissue.

Delivers functional copies of a gene to target cells using a viral vector, restoring expression of the deficient protein and correcting the underlying genetic defect.

Yes, Afamitresgene Autoleucel is an approved drug. It has reached clinical phase 4. It is classified as a Gene.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4802254. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.